Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You · 2026

Read Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis by Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570225.txt.

Description

Mingjun Rui and colleagues modelled whether adding blinatumomab to chemotherapy pays off for Hong Kong children with standard-risk B-cell leukaemia, publishing the cost-effectiveness analysis in 2026. The immune drug improved disease-free survival in a large trial, but its value from a public payer's view was untested. The team built a ten-year Markov model for average- and high-relapse-risk children, comparing chemotherapy alone with blinatumomab added first-line or second-line.

Both blinatumomab strategies fell below Hong Kong's willingness-to-pay threshold, with first-line use preferred in most probabilistic simulations. Drug cost and survival gains drove the results most. The authors conclude first-line blinatumomab appears cost-effective for newly diagnosed standard-risk paediatric B-cell leukaemia in this setting.

Catalog record

CREATORMingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13570225

Browse the full library · About the Tower of Babel